Bli medlem
Bli medlem

Du är här


Navamedic ASA: Navamedic launches new product in Nordic markets

Navamedic ASA (OSE: NAVA) today announced that the Company is launching a new
product in the Nordic markets. Expected annual sales of the product are more
than NOK 3 million.

Navamedic is taking over Nordic distribution and sales of the product
Florinef, which helps the adrenal glands retain sodium and act as a
replacement for cortisone when the body does not produce enough. The product
is an original pharmaceutical supplied by Navamedic's main supplier Aspen of
South Africa.

For further information, please contact interim CEO Håkan Josephsson,
telephone +46 706 742 533 or CFO Bjørn Lindholt, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and
distributing more than 120 products in the Nordic and Benelux markets. The
Company operates three business areas; Pharma Products, Medical Nutrition and
Consumer Care based on its relationship with a number of pharmaceutical
product manufacturers. Navamedic is listed on the Oslo Stock Exchange
(ticker: NAVA).


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Navamedic ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.